How to get from here to there: Macrophage recruitment in Alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 2, 2011, Pages 156-163

  Rezai Zadeh, K ^a   Gate, D ^a   Gowing, G ^a   Town, T ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Maxine Dunitz Neurosurgical Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abeta; Amyloid; Monocyte; Mononuclear phagocyte; Neurodegeneration

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; IMMUNOLOGICAL ADJUVANT; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ASEPTIC MENINGITIS; ASEPTIC MENINGOENCEPHALITIS; CELL INFILTRATION; DRUG SAFETY; HUMAN; IMMUNIZATION; IRRADIATION; MACROPHAGE; MACROPHAGE MIGRATION; MACROPHAGE RECRUITMENT; MENINGOENCEPHALITIS; MICROGLIA; NERVE CELL NECROSIS; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIATION CHIMERA; SIGNAL TRANSDUCTION;

EID: 79954514213     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720511795256017     Document Type: Article

References (74)

1. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol 132(1): 86-101 (1988).
2. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol 77(6): 569-75 (1989).
3. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24(3): 173-82 (1989).
4. Roher A, Gray EG, Paula-Barbosa M. Alzheimer's disease: coated vesicles, coated pits and the amyloid-related cell. Proc R Soc Lond B Biol Sci 232(1269): 367-73 (1988).
5. Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol 81(2): 116-24 (1990).
6. Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach B. Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can J Neurol Sci 16(4 Suppl): 535-42 (1989).
7. Wisniewski HM, Vorbrodt AW, Wegiel J, Morys J, Lossinsky AS. Ultrastructure of the cells forming amyloid fibers in Alzheimer disease and scrapie. Am J Med Genet Suppl 7: 287-97 (1990).
8. Wisniewski HM, Barcikowska M, Kida E. Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol 81(5): 588-90 (1991).
9. Akiyama H, Kondo H, Mori H, Kametani F, Nishimura T, Ikeda K, et al. The amino-terminally truncated forms of amyloid betaprotein in brain macrophages in the ischemic lesions of Alzheimer's disease patients. Neurosci Lett 219(2): 115-8 (1996).
10. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol 84(3): 225-33 (1992).
11. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17(3): 553-65 (1996).
12. Majumdar A, Chung H, Dolios G, Wang R, Asamoah N, Lobel P, et al. Degradation of fibrillar forms of Alzheimer's amyloid betapeptide by macrophages. Neurobiol Aging 29(5): 707-15 (2008).
13. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 24(2): 548-59 (2010).
14. Mitrasinovic OM, Murphy GM, Jr. Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. Neurobiol Aging 24(6): 807-15 (2003).
15. Mitrasinovic OM, Vincent VA, Simsek D, Murphy GM, Jr. Macrophage colony stimulating factor promotes phagocytosis by murine microglia. Neurosci Lett 344(3): 185-8 (2003).
16. Mitrasinovic OM, Murphy GM, Jr. Accelerated phagocytosis of amyloid-beta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J Biol Chem 277(33): 29889-96 (2002).
17. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184(9): 5333-43 (2010).
18. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400(6740): 173-7 (1999).
19. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-52 (2003).
20. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer's disease. Neuromolecular Med 7(3): 255-64 (2005).
21. Town T. Alternative Abeta immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets 8(2): 114-27 (2009).
22. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-9 (2000).
23. Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 9(2): 197-206 (2010).
24. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11(5): 556-61 (2005).
25. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS One 3(5): e2124 (2008).
26. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 27(46): 12721-31 (2007).
27. Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci 27(49): 13376-83 (2007).
28. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from betaamyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174(3): 1580-6 (2005).
29. Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, et al. Transcutaneous beta-amyloid immunization reduces cerebral betaamyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A 104(7): 2507-12 (2007).
30. Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, et al. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis 29(2): 336-53 (2008).
31. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100(21): 12462-7 (2003).
32. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7(3): 369-72 (2001).
33. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298(5597): 1379 (2002).
34. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1(1): 24 (2004).
35. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131(Pt 12): 3299-310 (2008).
36. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 118(1): 87-102 (2009).
37. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-23 (2008).
38. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239(4837): 290-2 (1988).
39. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 90(3): 986-93 (1997).
40. Kennedy DW, Abkowitz JL. Mature monocytic cells enter tissues and engraft. Proc Natl Acad Sci U S A 95(25): 14944-9 (1998).
41. Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M, et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7(12): 1356-61 (2001).
42. Ponomarev ED, Shriver LP, Maresz K, Dittel BN. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81(3): 374-89 (2005).
43. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, Zabel MD, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132(Pt 9): 2487-500 (2009).
44. Lewis CA, Solomon JN, Rossi FM, Krieger C. Bone marrowderived cells in the central nervous system of a mouse model of amyotrophic lateral sclerosis are associated with blood vessels and express CX(3)CR1. Glia 57(13): 1410-9 (2009).
45. Kang J, Rivest S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J Cell Biol 179(6): 1219-30 (2007).
46. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49(4): 489-502 (2006).
47. Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 25(48): 11125-32 (2005).
48. Keene CD, Chang RC, Lopez-Yglesias AH, Shalloway BR, Sokal I, Li X, et al. Suppressed Accumulation of Cerebral Amyloid {beta} Peptides in Aged Transgenic Alzheimer's Disease Mice by Transplantation with Wild-Type or Prostaglandin E2 Receptor Subtype 2-Null Bone Marrow. Am J Pathol 177(1): 364-54 (2010).
49. Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52(1): 70-7 (2005).
50. Town T. Alzheimer's Disease Beyond Abeta. Expert Rev Neurother 10(5): 671-5 (2010).
51. Zhu Y, Obregon D, Hou H, Giunta B, Erhart J, Fernandez F, et al. Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. J Cell Mol Med (2009) [Epub ahead of Print].
52. Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, et al. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 30(29): 9651-8 (2010).
53. Soulet D, Rivest S. Microglia. Curr Biol 18(12): R506-8 (2008).
54. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local selfrenewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10(12): 1538-43 (2007).
55. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 10(12): 1544-53 (2007).
56. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 8(6): 578-83 (2007).
57. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 106(4): 1261-6 (2009).
58. Laouar Y, Town T, Jeng D, Tran E, Wan Y, Kuchroo VK, et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105(31): 10865-70 (2008).
59. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19(1): 71-82 (2003).
60. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172(7): 4410-7 (2004).
61. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14(6): 681-7 (2008).
62. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T. Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (2010).
63. Rezai-Zadeh K, Gate D, Town T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 4(4): 462-75 (2009).
64. Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol 28(5): 443-60 (2004).
65. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171-97 (2008).
66. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25(4): 201-9 (2004).
67. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192(7): 1075-80 (2000).
68. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4): 432-8 (2007).
69. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12(11): 1361-3 (2009).
70. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics 4(4): 590-601 (2007).
71. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7): 917-24 (2006).
72. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 13(4): 411-3 (2010).
73. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28(1): 41-51 (2000).
74. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20(11): 4106-14 (2000).